Patent intelligence · US
US 10088485
Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand
Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand
Patent details — US 10088485
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 2, 2018
- Expiration
- Sep 27, 2038
- Applicant
- Regen Biopharma, Inc.
- Claims
- 16
- CPC classes
- A61K, A61K31/00, A61K31/427, A61K31/7088
Quick answer
US 10088485 (Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand) is held by Regen Biopharma, Inc.. Status: granted. Granted Oct 2, 2018. Expires Sep 27, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Regen Biopharma, Inc.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K31/00, A61K31/427, A61K31/7088
More from Regen Biopharma, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 10088485?
US 10088485 (Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand) is held by Regen Biopharma, Inc.. Status: granted. Granted Oct 2, 2018. Expires Sep 27, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10088485?
Regen Biopharma, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 10088485 expire?
Our index shows an expiration date of Sep 27, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.